Physician profile
Alan C Klein
NPI 1710069471
$2,108.18
in general payments reported to CMS, 2019-2025
20 companies · $350 in 2025
The $350 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $140 · 2021: $82.79 · 2022: $520 · 2023: $555 · 2024: $233 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,138.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $655.51 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $600.67 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $275.31 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $146.45 | 2019-2023 | |
| Exact Sciences Corporation | $97.82 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $43.17 | 2023-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $36.61 | 2022 | |
| Abbvie INC. | $35.59 | 2021 | |
| Esperion Therapeutics, INC. | $32.98 | 2025 | Nexletol |
| Corium, LLC | $26.48 | 2023 | Adlarity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.74 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $20.98 | 2023 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $16.22 | 2024 | Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $14.98 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.29 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $14.28 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $13.87 | 2022 | |
| Amarin Pharma, INC. | $13.68 | 2019 | |
| Sanofi Pasteur INC. | $11.94 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.